계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Aldagen
About
Aldagen develops regenerative cell therapies for inherited metabolic diseases, leukemia, critical limb ischemia and ischemic heart failure.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $14.30M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 19, 2006 | Series C | $14.30M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
The Trelys Funds
|
— | Series C |
